To hear about similar clinical trials, please enter your email below
Trial Title:
PD-1 Inhibitors With or Without Radiation in Advanced Melanoma
NCT ID:
NCT05498805
Condition:
the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma
Conditions: Official terms:
Melanoma
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Intervention model description:
radiation
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Radiation
Intervention name:
Radiation
Description:
According to the lesion sites, SBRT or hyperfractionated radiotherapy was used.
Arm group label:
controlled group
Arm group label:
experimental group
Summary:
This trial was a single-center, prospective, randomized controlled phase II trial. The
objective was to evaluate the efficacy and safety of PD-1 inhibitors with or without
radiotherapy in patients with advanced melanoma. At the same time, tissue and peripheral
blood samples of patients were collected for the determination of PD-L1 expression, ctDNA
and other biomarkers and results analysis to find prognostic or curative effect
predictors. A total of 92 patients were planned to be enrolled in this study.
Patients with advanced melanoma who met the inclusion criteria but did not meet the
exclusion criteria were enrolled in the study and received PD-1 inhibitors with or
without radiotherapy.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
Aged ≥18 years old, both sexes;
Malignant melanoma was confirmed by histology and pathology.
Braf, Nras, Ckit gene mutation status is unlimited.
Unresectable or metastatic melanoma, no matter lines of treatment;
Eastern Oncology Collaborative Group (ECOG) body condition score (PS) 0-2;
Predicted survival time exceeds 3 months.
Within 7 days (including 7 days) before screening, laboratory test data were used to
obtain neutrophil count ≥1.5×109/L, platelet count ≥90×109/L, hemoglobin ≥90g/L (no blood
transfusion within 14 days), and serum total bilirubin ≤1.25 times upper limit of normal
(ULN). ALT and AST≤ 2.5 x ULN (≤ 5X ULN in patients with liver metastases); Serum
creatinine ≤1.25 x ULN;
At least one radiotherapable lesion;
Subjects (or their legal representative/guardian) must sign an informed consent form
stating that they understand the purpose of the study, understand the required
procedures, and are willing to participate in the study.
Exclusion Criteria:
Received any investigational or antitumor drugs within 4 weeks prior to enrollment;
A history of other tumors within the past five years, except cured cervical cancer or
basal cell carcinoma of the skin;
A tumor emergency that requires immediate radiotherapy, such as symptomatic brain or
meningeal metastases, bone-related events, etc.
clinically significant active bleeding;
a woman who is pregnant or breastfeeding; Persons who are fertile but do not take
adequate contraceptive measures;
Alcoholism or drug addiction;
with active, or have a history and are likely to relapse of patients with autoimmune
diseases (such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel
disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerular
inflammation, etc.), or high risk (e.g., received organ transplants on immunosuppressive
therapy) of the patients. Exceptions are autoimmune hypothyroidism that requires only
hormone replacement therapy or skin conditions that do not require systemic treatment.
patients who required systemic treatment with corticosteroids (doses equivalent to > 10mg
prednisone/day) or other immunosuppressive agents within 14 days prior to enrollment or
during the study. Use topical or inhaled glucocorticoids, or short-term (≤7 days)
glucocorticoids for the prevention or treatment of non-autoimmune, infrequently occurring
allergic diseases.
Critical organ failure or other serious disease, including interstitial pneumonia,
clinically relevant coronary disease, cardiovascular disease, or a history of myocardial
infarction, congestive heart failure, unstable angina, symptomatic pericardial effusion,
or unstable arrhythmia in the 6 months prior to enrollment;
Have a history of human immunodeficiency virus infection, another acquired or congenital
immunodeficiency disease, or a history of organ transplantation, or stem cell
transplantation;
A patient with active chronic hepatitis B or active hepatitis C. HBV carriers, medically
stable hepatitis B (DNA titer ≤103 copies /ml), and cured hepatitis C (HCV RNA negative)
patients were eligible for enrollment.
A history of severe neurological or psychiatric problems; Severe infection; Active
disseminated intravascular coagulation or other comorbidities that, in the investigator's
judgment, seriously compromise patient safety or interfere with study completion.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Fudan University Shanghai Cencer Center
Address:
City:
Shanghai
Zip:
200032
Country:
China
Start date:
August 15, 2022
Completion date:
August 15, 2025
Lead sponsor:
Agency:
Fudan University
Agency class:
Other
Source:
Fudan University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05498805